Effect of sulodexide on aortic vasodilation capacity and associated morphological changes in rats with streptozotocin-induced diabetes;Efecto del sulodexide sobre la capacidad de relajación y alteraciones estructurales de la arteria aorta en ratas diabéticas por estreptozotocina

Investigacion Clinica

Volumn 51, Issue 4, 2010, Pages 467-477

  Vásquez, José ^a   Mathison, Yaira ^a   Romero Vecchione, Eduardo ^a   Suárez, Claudia ^b  

^a Escuela de Medicina Jose Maria Vargas   (Venezuela)

^b UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

Author keywords

Diabetes; Endothelial dysfunction; Streptozotocin; Sulodexide

Indexed keywords

ACETYLCHOLINE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; STREPTOZOCIN; SULODEXIDE; ANTIDIABETIC AGENT; GLYCOSAMINOGLYCAN;

ADVENTITIA; ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; HISTOLOGY; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INTIMA; MICROSCOPY; MORPHOLOGY; NONHUMAN; RAT; SMOOTH MUSCLE TONE; SPRAGUE DAWLEY RAT; STREPTOZOCIN DIABETES; VASCULAR RING; VASCULARIZATION; VASODILATATION; ANIMAL; AORTA DISEASE; COMPARATIVE STUDY; DIABETIC ANGIOPATHY; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL DIABETES MELLITUS; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; ULTRASTRUCTURE; VASCULAR ENDOTHELIUM;

ACETYLCHOLINE; ANIMALS; AORTA; AORTIC DISEASES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; DRUG EVALUATION, PRECLINICAL; ENDOTHELIUM, VASCULAR; GLYCOSAMINOGLYCANS; HYPOGLYCEMIC AGENTS; MALE; NITROPRUSSIDE; RATS; RATS, SPRAGUE-DAWLEY; TUNICA INTIMA; VASODILATION;

EID: 79953742185     PISSN: 05355133     EISSN: 05355133     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288:373-376.
2. Moncada S, Palmer RM, Higgs A. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43:109-142.
3. Simón A, Castro A, Kaski JC. Progress in the knowledge of endothelial dysfunction and its application in clinical practice. Rev Esp Cardiol 2001; 54:211-217.
4. Badimón L, Martínez-González J. Endotelio en la protección vascular: nuevos conocimientos. Rev Esp Cardiol 2002; 55:17-26.
5. Ceballos RG, Ramírez SI, Calzada-Mendoza CC, Olivares-Corichi IM. Disfunción endotelial y estrés oxidativo. Rev Endocrinol Nutr 2006; 14:233-236.
6. Power AC. Diabetes Mellitus. En Braundwald E, Wilson J, Fauci A, Kasper D, Hauser S, Longo Djameson JL Eds, Harrison Principios de Medicina Interna, 15a. ed. Vol. II, McGraw Hill Interamericana Edito-res, SA de CV, México DF, 2002. P 2467-2500.
7. Hadi HA, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vas Health Risk Manag 2007; 3:853-876.
8. Panus C, Mota M, Vladu D, Vanghelie L, Raducanu CL. The endothelial dysfunction in diabetes mellitus. Rom J Intern Med 2003; 41:27-33.
9. Deckert T, Felt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989; 32: 219-226.
10. Stehouwer C, Henry R, Dekker J, Nijpels G, Heine R, Bouter L. Microalbuminuria is associated with impaired brachial artery, flow mediated vasodilation in the elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction. The Hoorn Study. Kydney Int 2004; 6:S42-44.
11. Gambaro G, van der Woude F. Glycosaminoglycans: use in treatment of diabetic nephropathy. J Am Soc Nephrol 2000; 11:359-368.
12. Myrup B, Hansen P, Jensen T., Kofoed-Enevoldsen A, Feldt-Rasmussen B, Gram J, Kluft C, Jespersen J, Deckert T. Effect of low-dose of heparin on urinary excretion in insulin-dependent diabetes mellitus. Lancet 1995; 345:421-422.
13. Tamsma J, van der Woude Y, Lemkes H. Effect of sulphated glycosaminoglycams on albuminuria in patients with overt diabectic (type 1) nephrophaty. Nephrol Dial Transplant 1996; 11(1):182-185.
14. van der Pijl J, Lemkes H, Frölich M, van der Woude F, van der Meer F, van Es L. Effect of danaparoid sodium on proteinuria, von Willebrand factor, and hard exudates in patients with diabetes mellitus type 2. J Am Soc Neprhol 1999; 10:1331-1336.
15. Ofosu F. Pharmacological actions of sulodexide. Semin Thromb Hemost. 1998; 24:127-138
16. Crepaldi G, Rossi A, Coscetti G, Abbruzzese E, Calveri U, Calabro A. Sulodexide oral administration influences blood viscosity and fibrinolisis. Drug Exptl. Clin Res 1992; 18:189-195.
17. Gallagher J, Lyon M, Steward W. Structure and function of heparan sulphate proteoglycans. Biochem J 1986; 236:313-325.
18. Wu V, Wilson B, Cohen M. Disturbances in glomerular basement membrane glycosaminoglycans in experimental diabetes. Diabetes 1987; 36:679-683
19. Deckert T, Kofoed-Enevoldsen A, Borch-Johnsen K, Rasmussen B, Jensen T. Microalbuminuria: Implications for micro and macrovascular diseases. Diabetes Care 1992; 15 (9):1181-1191.
20. Jensen T. Pathogenesis of diabetic vascular disease: evidence for the role of reduced heparan sulfate proteoglycan. Diabetes 1997; 46(S2):S98-S100.
21. Lewis E, Xu X. Abnormal glomerular permeability characteristic in diabetic nephropathy. Implications for the therapeutic use of low-molecular weight heparin. Diabetes Care 2008; 31(S2): S202-206.
22. Rohrbach D, Hassel J, Kleinman H, Martín G. Alterations in the basement membrane (heparan sulfate) proteoglycan in dibetic mice. Diabetes 1982; 31:185-188.
23. Kanwar Y, Rosenzweig L, Linker A, Jakuboswski M. Decreased the novo synthesis of glomerular proteoglycans in diabetes: Biochemical and autoradiographic evidences. Proc Natl Acad Sci USA 1983; 80:2272-2275.
24. Parthasarathy N, Spiro R. Effect of diabetes on the glycosaminoglycans component of the human glomerular basement membrane. Diabetes 1982; 31:738-741.
25. Wasty F, Alavi MZ, Moore S. Distribution of glycosaminoglycans in the intima of human aortas: changes in atherosclerosis and diabetes mellitus. Diabetología 1993; 36(4):316-322.
26. Gambaro G, Baggio B. Role of glycosaminoglycans in diabetic nephropathy. Acta Diabetol 1992; 29:149-155.
27. Gambaro G, Venturini A, Noonam D, Fries W, Re G, Garbisa S, Milanesi C, Pesarini A, Borsatti A, Marchi E, Bruno B. Treatment with a glycosaminoglycans formulation ameliorates experimental diabetic nephropaty. Kidney Int 1994; 46:797-806.
28. Cortinovis M, Cattaneo D, Perico N, Remuzzi G. Investigational drugs for diabetic nephropathy. Exp Opin Investig Drugs 2008; 17:1487-1500.
29. Weiss R, Niecestro R, Raz I. The role of sulodexide in the treatment of diabetic nephropathy. Drugs 2007; 67:2681-2696.
30. Solini A, Carraro A, Barzon I, Crepaldi G. Therapy with glycosaminoglycans lower albumin excretion rate in non-insulin dependent diabetic patients with macroalbuminuria. Diab Nutr Metab 1994; 7: 304-307.
31. Solini A, Vergnani L, Ricci F, Crepaldi G. Glycosaminoglycans delay the progression of nephropathy in NIDDM. Diabetes Care 1997; 20(5):819-823.
32. Velussi M, Cernigoi A, Dapas F, De Monte A. Glycosaminoglycans oral therapy reduces microalbuminuria, blood fibrinogen levels and limb arteriopthy clinical signs in patients with non-insulin dependent diabetes mellitus. Diab Nutr Metab 1996; 9:53-58.
33. Dedov I, Shestakova M, Vorontzov A, Palazzini E. A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy. Nephrol Dial Transplant 1997; 12:2295-2300.
34. Achour A, Kacem M, Dibej K, Skhiri H, Bouraoui S, El May M. One year course of oral sulodexide in the management of diabetic nephropathy. J Nephrol 2005; 18(5): 568-574.
35. Gambaro G, Kinalska I, Oksa A, Pont́uch P, Hertlova M, Olsovsky J, Manitius J, Fedele D, Czekalski S, Perusicova J, Skrha J, Taton J, Greszczak W, Crepaldi G. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: The Di.N.A.S. randomized trial. J Am Soc Nephrol 2002; 13(6): 1615-1625.
36. Lambers Heerspink HJ, Greene T, Lewis J, Itamas R, Rohde R, Hunsicker G, Schwartz S, Aronoff S, Katz M, Eisner G, Mersey J, Wiegmann T for the Collaborative group. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol Dial Transplant 2008; 23:1946-1954.
37. Lambers-Heerspink HJ, Fowel MJ, Volgi J, Reutens AT, Klein I, Herskovits TA, Packham DK, Fraser IR, Schrtz SL, Abeterusso C, Lewis J, Collaborative Study Group. Rationale for and study design of the sulodexide trial in type 2 diabetic, hypertensive patients with microalbuninuria or overt nephropathy. Diabet Med 2007; 24(11):1290-1295.
38. Clinical Trials. NCT001130208 en http://www.clinicalstrials.gov
39. Clinical Trials. NCT00130312 en http://www.clinicalstrials.gov
40. Kristova V, Liskova S, Sotnikova R, Vojtko R, Kurtansky A. Sulodexide improves endothelial dysfunction in streptozotosin-induced diabetes in rats. Physiol Rev 2008; 57:491-494
41. Mathison Y, Garrido MR, Israel A, Quero Z, Fernández H. Efecto del glicosaminoglicano sulodexide sobre la actividad de la sintasa del óxido nítrico en la corteza renal de ratas con diabetes tipo 1. Rev Latinoamer Hiperten 2008; 3(6):182-188.
42. Tasatargil A, Golbasi I, Sadan G, Karasu E. Unfraccionated heparin produces vasodilatory action on human internal mammary artery by endothelium-dependent mechanism. J Cardiovasc Pharmacol 2005; 45:114-119.
43. Li J, Hajarizadeh H, LaRosa C, Rohrer M, Vander-Salm T, Cutler B. Heparin and protamine stimulate the production of nitric oxide. J Cardiovasc Surg. (Torino) 1996; 37:445-452
44. Mochisuki S, Vink H, Hiramatsu O, Kajita T, Shigeto F, Spaan J, Kajiya F. Role of hyaluronic acid glicosaminoglycans in shear-induced endothelium-derived nitric oxide release. Am J Physiol Heart Circ Physiol 2003; 285:H722-726
45. Park HY, Kang S, Kim GY, Jang Y, Know HM, Shim WH, Cho SY, Cho SH. Inhibition of neointimal proliferation of rat carotic artery by sulodexide. J Korean Med Sci 1997; 12:210-214.
46. Iacoviello L, DAdamo MC, Pawlak K, Polishchurk R, Wollny T, Buczko W, Donati MB. Antithrombotic activity of dermatan sulphates, heparins and their combination in animal models of arterial thrombosis. Thromb Haemost 1996; 76(6): 1102-1107.
47. Ceriello A, Quatraro A, Marchi E, Barbantini M, Giugliano D. Impaired fibrinolytic response to increased thrombin activation in type 1 diabetes mellitus: effects of the glycosaminoglycan sulodexide. Diabete Metab 1993; 19(2): 225-229.